Real-world analysis of survival outcomes in advanced EGFR-mutant NSCLC patients treated with platinum-pemetrexed after EGFR-TKI treatment failure

Introduction: EGFR tyrosine kinase inhibitors (TKIs) are the standard therapy for non-small-cell lung cancer (NSCLC) patients with EGFR-activating mutations in the first-line setting. Despite initial efficacy, resistance to EGFR-TKIs often develops, and platinum-based chemotherapy is the predominant...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Zong-Han Yao, Wei-Yu Liao, Chin-Yao Yang, Chao-Chi Ho, Jin-Yuan Shih, Kuan-Yu Chen, James Chih-Hsin Yang, Chong-Jen Yu
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2025-08-01
Serija:	Journal of the Formosan Medical Association
Teme:	Non-small cell lung cancer Epidermal growth factor receptor Tyrosine kinase inhibitors Platinum doublet Pemetrexed
Online dostop:	http://www.sciencedirect.com/science/article/pii/S0929664624003851
Oznake:	Označite Brez oznak, prvi označite!